Results 121 to 130 of about 53,940 (250)

Management Strategies for Refractory Esophageal Varices

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Refractory esophageal varices that are difficult to control or unresponsive to endoscopic treatment remain a major clinical challenge in the management of portal hypertension. This review provides a comprehensive overview of treatment strategies for these cases, along with a comparative analysis of the American Association for the Study of ...
Keita Maki, Hiroaki Haga, Yoshiyuki Ueno
wiley   +1 more source

Water and wisdom: Hydration as a defence against dementia

open access: yes
Experimental Physiology, EarlyView.
David C. Byfield, Damian M. Bailey
wiley   +1 more source

3,4‐Methylenedioxymethamphetamine (MDMA) does not induce robust psychomotor activation and 50‐kHz ultrasonic vocalisations in tryptophan hydroxylase 2 (Tph2)‐deficient rats lacking serotonin in the central nervous system

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 7, Page 1539-1556, April 2026.
Background and Purpose 3,4‐Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a psychostimulant with entactogenic properties and known to induce arousal and euphoria. As an amphetamine derivate, MDMA acts on the monoamine systems in the brain and stimulates release of dopamine (DA), noradrenaline (NA) and serotonin (5‐HT), yet their ...
Tianhua Wang   +2 more
wiley   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2661-2671, April 2026.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan   +7 more
wiley   +1 more source

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3254-3263, April 2026.
Abstract Aims Sotagliflozin, an inhibitor of sodium‐glucose co‐transporter (SGLT)‐1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).
Massimo Nardone   +6 more
wiley   +1 more source

First Detection of Lactococcus formosensis subsp. formosensis in Rainbow Trout (Oncorhynchus mykiss) in Europe

open access: yesJournal of Fish Diseases, Volume 49, Issue 4, April 2026.
ABSTRACT Lactococcus garvieae, Lactococcus petauri and Lactococcus formosensis are etiological agents of piscine lactococcosis, a disease reported in Italy since the early 1990s and linked to significant aquaculture losses. To the best of our knowledge, this study reports the first detection of L. formosensis subsp. formosensis in farmed rainbow trout (
Silvia Colussi   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy